September 1, 2016

View Issues

Oral Anticoagulation Reversal

This review discusses anticoagulant medications and reversal agents.

Read more

Issue Date: September 1, 2016

Financial Disclosure: To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Dr. Farel (CME question reviewer) owns stock in Johnson & Johnson. Dr. Stapczynski (editor) owns stock in Pfizer, Johnson & Johnson, Walgreens Boots Alliance Inc., GlaxoSmithKline, Bristol Myers Squibb, and AxoGen. Dr. Hatfield (author) is a retained (nonpromotional) consultant for a product under development for Portola Pharmaceuticals. Dr. Mehrotra (author) is a stockholder and board member for MedScribes. Dr. Pollack (peer reviewer) has received grant/research support and is a retained consultant for: Boehringer Ingelheim, Daiichi Sankyo; retained consultant for Janssen Pharma, BMS/Pfizer Alliance. Dr. Schneider (editor), Ms. Fessler (nurse planner), Dr. Buff (author), Dr. Kessler (author), Ms. Mark (executive editor), Ms. Coplin (executive editor), and Mr. Landenberger (editorial and continuing education director) report no financial relationships with companies related to the field of study covered by this CME activity.

Emergency Medicine Reports – September 1, 2016

September 1, 2016

Oral Anticoagulation Reversal